Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity

Inflammopharmacology

Volumn 16, Issue 4, 2008, Pages 155-161

  Laufer, S ^a   Greim, C ^b   Luik, S ^a   Ayoub, S S ^c   Dehner, F ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b TEVA PHARMACEUTICALS   (Israel)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cyclo oxygenase; Drug screening; Human whole blood assay; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; CELECOXIB; CREMOPHOR; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; DICLOFENAC; DIMETHYL SULFOXIDE; ETORICOXIB; IBUPROFEN; INDOMETACIN; KETOPROFEN; LIPOPOLYSACCHARIDE; LORNOXICAM; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; THROMBOXANE SYNTHASE INHIBITOR; VALDECOXIB;

ARTICLE; BLOOD; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL ASSAY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ETHANOL; GLYCEROL; HUMANS; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; REPRODUCIBILITY OF RESULTS; SOLUBILITY; VEHICLES;

EID: 51349110031     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-008-8007-x     Document Type: Article

References (46)

1. Argentieri, D. C., Ritchie, D. M., Ferro, M. P., Kirchner, T., Wachter, M. P., Anderson, D. W. et al. (1994). Tepoxalin: A dual cyclooxygenase/5-lipoxygenase inhibit or of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 271,1399-408.
2. Berg, J., Fellier, H., Christoph, T., Grarup, J., Stimmeder, D. (1999). The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res 48, 369-79.
3. Blain, H., Boileau, C., Lapicque, F., Nedelec, E., Loeuille, D., Guillaume, C. et al. (2002). Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol 53, 255-65.
4. Brideau, C., Kargman, S., Liu, S., Dallob, A. L., Ehrich, E. W., Rodger, I. W. et al. (1996). A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45, 68-74.
5. Brune, K., Geisslinger, G., Menzen-Soglowek, S. (1992). Pure enantiomers of 2-arylpropionic acids: Tools in pain research and improved drugs in rheumatology. J Clin Pharmacol 32, 944-52.
6. Burch, J. W., Stanford, N., Majerus, P. W. (1978). Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61, 314-9.
7. Carabaza, A., Cabre, F., Rotllan, E., Gomez, M., Gutierrez, M., Garcia, M. L. et al. (1996). Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs. J Clin Pharmacol 36, 505-12.
8. Chauret, N., Yergey, J. A., Brideau, C., Friesen, R. W., Mancini, J., Riendeau, D. et al. (2001). In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 11, 1059-62.
9. de Leval, X., Delarge, J., Devel, P., Neven, P., Michaux, C., Masereel, B. et al. (2001). Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood. Prostaglandins Leukot Essent Fatty Acids 64, 211-6.
10. Fu, J. Y., Masferrer, J. L., Seibert, K., Raz, A., Needleman, P. (1990). The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265, 16737-40.
11. Funk, C. D., Funk, L. B., Kennedy, M. E., Pong, A. S., Fitzgerald, G. A. (1991). Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 5, 2304-12.
12. Goppelt-Struebe, M. (1995). Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme expression. Prostaglandins Leukot Essent Fatty Acids 52, 213-22.
13. Hempel, S. L., Monick, M. M., Hunninghake, G. W. (1994). Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 93, 391-6.
14. Jacobs, P. (1998). Entwicklung von in vitro-Testsystemen zur Überprüfung entzündungsrelevanter Mediatoren der Arachidonsäurekaskade bzw. des Interleukinstoffwechsels (1998)
15. Jones, D. A., Fitzpatrick, F. A. (1990). "Suicide" inactivation of thromboxane A2 synthase. Characteristics of mechanism-based inactivation with isolated enzyme and intact platelets. J Biol Chem 265, 20166-71.
16. Kato, K., Ohkawa, S., Terao, S., Terashita, Z., Nishikawa, K. (1985). Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. J Med Chem 28, 287-94.
17. Komhoff, M., Grone, H. J., Klein, T., Seyberth, H. W., Nusing, R. M. (1997). Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 272, F460-F8.
18. Laneuville, O., Breuer, D. K., Dewitt, D. L., Hla, T., Funk, C. D., Smith, W. L. (1994). Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271, 927-34.
19. Laufer, S., Zechmeister, P., Klein, T. (1999). Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors. Inflamm Res 48,133-8.
20. Lee, S. H., Soyoola, E., Chanmugam, P., Hart, S., Sun, W., Zhong, H. et al. (1992). Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 267, 25934-8.
21. Maclouf, J., Kindahl, H., Granstrom, E., Samuelsson, B. (1980). Thromboxane A2 and prostaglandin H2 form covalently linked derivatives with human serum albumin. Adv Prostaglandin Thromboxane Res 6, 283-6.
22. Martyn, C. (2003). Anti-inflammatory drugs and Alzheimer's disease. Brit Med J 327, 353-4.
23. McGeer, P. L., McGeer, E., Rogers, J., Sibley, J. (1990). Anti-inflammatory drugs and Alzheimer's disease. Lancet 335, 1037.
24. Meade, E. A., Smith, W. L., DeWitt, D. L. (1993). Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268, 6610-4.
25. Mitchell, J. A., Saunders, M., Barnes, P. J., Newton, R., Belvisi, M. G. (1997). Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol 51, 907-12.
26. Nusing, R., Ullrich, V. (1990). Immunoquantitation of thromboxane synthase in human tissues. Eicosanoids 3, 175-80.
27. Nusing, R., Schneider-Voss, S., Ullrich, V. (1990). Immunoaffinity purification of human thromboxane synthase. Arch Biochem Biophys 280, 325-30.
28. Patrignani, P., Volpi, D., Ferrario, R., Romanzini, L., Di Somma, M., Patrono, C. (1990). Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. Eur J Pharmacol 191, 83-8.
29. Patrignani, P., Panara, M. R., Greco, A., Fusco, O., Natoli, C., Iacobelli, S. et al. (1994). Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271, 1705-12.
30. Patrono, C., Ciabattoni, G., Pinca, E., Pugliese, F., Castrucci, G., De Salvo, A. et al. (1980). Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17, 317-27.
31. Putter, J. (1982). Biotransformation of acetylsalicylic acid. In Segre G, Ohnmeiss H (eds): ASA. International Symposium on Present State of Acetylsalicylic Acid in Research and Therapeutic Application. Florence, Italy: O.I.C. Medical Press, pp. 49-59.
32. Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R. et al. (2004). Rofecoxib Protocol 091 Study Group: Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66-71.
33. Riendeau, D., Percival, M. D., Boyce, S., Brideau, C., Charleson, S., Cromlish, W. et al. (1996). Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121, 105-17.
34. Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dube, D., Ethier, D. et al. (2001). Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296, 558-66.
35. Rote Liste®. Drug information for Germany (including accreditation and special medical devices). Publisher: Rote Liste® Service GmbH, Frankfurt, Main.
36. Smith, J. B., Willis, A. L. (1971). Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 231, 235-7.
37. Smithers, M. (Macclesfield, GB): Therapeutic agents. United States Patent 4925869 1990.
38. Strand, V. (2007). Are Cox-2 inhibitors preferable to non-selective non steroidal anti inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 370, 2138-51.
39. Tacconelli, S., Capone, M. L., Sciulli, M. G., Ricciotti, E., Patrignani, P. (2002). The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin 18, 503-11.
40. Tereshita, Z., Imura, Y., Tanabe, M., Kawazoe, K., Nishikawa, K., Terao, S. (1986). CV-4151 a potent, selective thromboxane A2 synthetase inhibitor. Throm Research 41[2], 223-37.
41. 2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. Throm Research 77[5], 411-21.
42. Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., Vane, J. R. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96, 7563-8.
43. Warner, T., Mitchell, J. (2008). COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371, 270-3.
44. Williams, K. M. (1990). Enantiomers in arthritic disorders. Pharmacol Ther 46, 273-95.
45. Yokoyama, C., Miyata, A., Ihara, H., Ullrich, V., Tanabe, T. (1991). Molecular cloning of human platelet thromboxane A synthase. Biochem Biophys Res Commun 178:1479-84.
46. Young, J. M., Panah, S., Satchawatcharaphong, C., Cheung, P. S. (1996). Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res 45, 246-53.